Michael Xiang
Resident in Radiation Oncology - Radiation Therapy

Publications

PUBLICATIONS

• Survival of patients with head and neck cancer treated with definitive radiotherapy and concurrent cisplatin or concurrent cetuximab: A Surveillance, Epidemiology, and End Results-Medicare analysis. *Cancer*
  Xiang, M., Holsinger, F. C., Colevas, A. D., Chen, M. M., Le, Q., Beadle, B. M.
  2018

• Comparative Effectiveness and Toxicity of Cetuximab or Cisplatin With Concurrent Radiation for Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck: A Population-Based Analysis
  Xiang, M., Holsinger, F., Chen, M., Colevas, A., Beadle, B.
  ELSEVIER SCIENCE INC. 2018: E16

• Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anticancer agent *BLOOD*
  2016; 128 (14): 1845-1853

• Brachytherapy boost and cancer-specific mortality in favorable high-risk and other high-risk prostate cancer.
  Muralidhar, V., Xiang, M. I., Orio, P. F., Martin, N. E., Beard, C., Feng, F., Hoffman, K. E., Nguyen, P. L.
  AMER SOC CLINICAL ONCOLOGY. 2016

• Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer *JOURNAL OF CONTEMPORARY BRACHYTHERAPY*
  Muralidhar, V., Xiang, M., Orio, P. F., Martin, N. E., Beard, C. J., Feng, F. Y., Hoffman, K. E., Nguyen, P. L.
  2016; 8 (1): 1-6